Table 6. Impact of cytogenetic risk... | American Society of Hematology

Table 6.

Impact of cytogenetic risk group on outcome to identical combination chemotherapy regimens within age group

Hierarchical cytogenetic risk group by age	No. patients randomized to DAT or ADE	Status after course 1
Hierarchical cytogenetic risk group by age	No. patients randomized to DAT or ADE	CR, %	Induction death, %	Resistant disease, %
Younger than 55 years
Overall	1500	59	8	33
Favorable	354	64^6-150	9	27^6-150
No abnormality	646	63	6	31
Other intermediate	345	57	7	36
Noncomplex adverse	71	31	15	54
Complex	84	43	12	45
Older than 55 years
Overall	568	43	20	37
Favorable	39	56^6-150	18	26^6-150
No abnormality	270	49	23	29
Other intermediate	152	39	16	44
Noncomplex adverse	35	37	11	51
Complex	72	26	22	51

Hierarchical cytogenetic risk group by age	No. patients randomized to DAT or ADE	Status after course 1
Hierarchical cytogenetic risk group by age	No. patients randomized to DAT or ADE	CR, %	Induction death, %	Resistant disease, %
Younger than 55 years
Overall	1500	59	8	33
Favorable	354	64^6-150	9	27^6-150
No abnormality	646	63	6	31
Other intermediate	345	57	7	36
Noncomplex adverse	71	31	15	54
Complex	84	43	12	45
Older than 55 years
Overall	568	43	20	37
Favorable	39	56^6-150	18	26^6-150
No abnormality	270	49	23	29
Other intermediate	152	39	16	44
Noncomplex adverse	35	37	11	51
Complex	72	26	22	51

Mantel-Haenszel test for trend was performed, P values for effect of hierarchical cytogenetic risk group on status after course 1 within age group. DAT indicates daunorubicin, ara-C, 6-thioguanine; ADE, ara-C, daunorubicin, etoposide; CR, complete remission.

F6-150

P < .001.

View Large

This Feature Is Available To Subscribers Only